A few recent articles in the AFR on API. Some have suggested...

A few recent articles in the AFR on API. Some have suggested that API might need to sell the Priceline pharmacies. Soul Pattinson, one of API's largest shareholders is said, in two different articles, to be supportive (one article) and not supportive (in the other article) of such an asset sale (Solomon Lew controls Soul Pattinson- I didn't know that prior). API/Stephen Roche, doesn't want to sell, as the pharmacies are considered "flagship" assets of the company- a company maker, if you will.

A merger between SIP and API was mentioned, but the Metcash deal was said to be watched for an outcome, as the SIP/API deal would go similarly. The Metcash deal was knocked back by the ACCC, although it is going to court as an appeal against the knockback.

My platform still shows an NTA of 72c/sh for API (SIP has an NTA of 69c/sh), which makes API good value. I'm not fond of a possibility of a court case that API flouted in its "we reserve our rights" from the last ANN.

API reports in October.